Headlands Technologies LLC Buys Shares of 9,652 C4 Therapeutics, Inc. (NASDAQ:CCCC)

Headlands Technologies LLC purchased a new position in C4 Therapeutics, Inc. (NASDAQ:CCCC) in the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 9,652 shares of the company’s stock, valued at approximately $45,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Lighthouse Investment Partners LLC bought a new stake in C4 Therapeutics in the fourth quarter worth about $124,000. Entropy Technologies LP bought a new stake in shares of C4 Therapeutics in the 1st quarter worth approximately $126,000. Caxton Associates LP bought a new stake in shares of C4 Therapeutics in the 1st quarter worth approximately $172,000. SG Americas Securities LLC acquired a new stake in C4 Therapeutics during the first quarter valued at approximately $183,000. Finally, Hussman Strategic Advisors Inc. bought a new stake in C4 Therapeutics during the second quarter worth approximately $194,000. 78.81% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, BMO Capital Markets reaffirmed an “outperform” rating and set a $20.00 target price on shares of C4 Therapeutics in a research report on Tuesday, August 6th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $9.29.

C4 Therapeutics Price Performance

NASDAQ:CCCC opened at $6.46 on Wednesday. The stock’s 50-day moving average is $6.16 and its two-hundred day moving average is $6.43. The stock has a market cap of $444.49 million, a PE ratio of -2.73 and a beta of 3.05. C4 Therapeutics, Inc. has a fifty-two week low of $1.06 and a fifty-two week high of $11.88.

C4 Therapeutics (NASDAQ:CCCC) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.11. The firm had revenue of $12.01 million for the quarter, compared to analyst estimates of $6.88 million. C4 Therapeutics had a negative net margin of 367.17% and a negative return on equity of 44.60%. On average, equities research analysts anticipate that C4 Therapeutics, Inc. will post -1.57 earnings per share for the current year.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.